Welcome to LookChem.com Sign In|Join Free

CAS

  • or

5351-07-5

Post Buying Request

5351-07-5 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

5351-07-5 Usage

General Description

2-(4-Methoxyphenyl)-2-methylpropanenitrile is a chemical compound that belongs to the class of nitriles. It is commonly used in the synthesis of various organic compounds and pharmaceuticals. The compound is identified by its molecular formula C11H13NO and has a molecular weight of 175.23 g/mol. It is a clear, colorless liquid at room temperature and is soluble in organic solvents such as ethanol and ether. The compound is known to be toxic if ingested and can cause irritation to the skin and eyes upon contact. It is important to handle and use this chemical with proper safety precautions in a well-ventilated area.

Check Digit Verification of cas no

The CAS Registry Mumber 5351-07-5 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 5,3,5 and 1 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 5351-07:
(6*5)+(5*3)+(4*5)+(3*1)+(2*0)+(1*7)=75
75 % 10 = 5
So 5351-07-5 is a valid CAS Registry Number.
InChI:InChI=1/C11H13NO/c1-11(2,8-12)9-4-6-10(13-3)7-5-9/h4-7H,1-3H3

5351-07-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name 2-(4-Methoxyphenyl)-2-methylpropanenitrile

1.2 Other means of identification

Product number -
Other names 2-(4-Methoxy-phenyl)-2-methyl-propionitril

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:5351-07-5 SDS

5351-07-5Relevant articles and documents

Palladium-Catalyzed Distal m-C-H Functionalization of Arylacetic Acid Derivatives

Srinivas, Dasari,Satyanarayana, Gedu

supporting information, p. 7353 - 7358 (2021/10/01)

Herein, we present m-C-H olefination on derivatives of phenylacetic acids by tethering with a simple nitrile-based template through palladium catalysis. Notably, the versatility of the method is evaluated with a wide range of phenylacetic acid derivatives for obtaining the meta-olefination products in fair to excellent yields with outstanding selectivities under mild conditions. Significantly, the present strategy is successfully exemplified for the synthesis of drugs/natural product analogues (naproxen, ibuprofen, paracetamol, and cholesterol).

EP300/CREBBP INHIBITOR

-

Paragraph 0344; 0345; 0372; 0373, (2020/05/30)

The present invention provides a compound having excellent histone acetyltransferase inhibitory activity against EP300 and/or CREBBP, or a pharmacologically acceptable salt thereof. The compound is represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein ring Q1, ring Q2, R1, R2, R3 and R4 respectively have the same meanings as defined in the specification.

N2-(2-METHOXYPHENYL)PYRIMIDINE DERIVATIVE, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION FOR CANCER PREVENTION OR TREATMENT CONTAINING SAME AS ACTIVE INGREDIENT

-

Paragraph 0302; 0303; 0304; 0305; 0306, (2018/05/03)

The present invention relates to a N2-(2-methoxyphenyl)pyrimidine derivative, a preparation method thereof, and a pharmaceutical composition for the prevention or treatment of cancer comprising the same as an active ingredient. The N2-(2-methoxyphenyl)pyrimidine derivative, the optical isomer thereof, or the pharmaceutically acceptable salt thereof of the present invention is very effective in suppressing anaplastic lymphoma kinase (ALK) activity and as a result it can improve the effectiveness of treatment on cancer cells having anaplastic lymphoma kinase (ALK) fusion proteins such as EML4-ALK and NPM-ALK, so that it can be effectively used as a pharmaceutical composition for preventing or treating cancer.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 5351-07-5